Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that is focused on developing medications for addiction and related disorders. The company's mission is to provide innovative and effective solutions to help people struggling with addiction achieve long-term recovery.
Adial was founded in 2010 and is headquartered in Charlottesville, Virginia. The company is currently developing a drug called AD04, which is designed to treat alcohol use disorder (AUD). AD04 is a selective serotonin-3 (5-HT3) antagonist that works by reducing the craving for alcohol and other substances.
AUD is a chronic, relapsing brain disease that is characterized by the compulsive use of alcohol despite its negative consequences. It is estimated that approximately 14.5 million adults in the United States have AUD, and it is a leading cause of preventable death and disease worldwide.
Currently, there are only three drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of AUD. These drugs, which include naltrexone, acamprosate, and disulfiram, have limited effectiveness and are associated with significant side effects.
AD04 has the potential to be a game-changer in the treatment of AUD. The drug has shown promising results in clinical trials, with a significant reduction in the number of heavy drinking days and an improvement in quality of life. AD04 is also associated with fewer side effects than currently available treatments.
In addition to its focus on developing treatments for AUD, Adial is also exploring the use of its technology in other areas of addiction and related disorders. The company is currently developing a drug called AD-101, which is designed to treat post-traumatic stress disorder (PTSD) and other anxiety-related disorders.
Adial Pharmaceuticals Inc. is a company that is committed to developing innovative and effective solutions to help people struggling with addiction and related disorders. With its focus on developing novel treatments for AUD and exploring the use of its technology in other areas of addiction and related disorders, Adial is well-positioned to make a significant impact on the lives of those affected by these conditions.
Comments